FindTrial
Sign In

Effects of expectations, medication and placebo during the Quantified Behavior Test in patients with untreated ADHD.

Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivity in patiens with untreated ADHD.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-005045-53-SE
Enrollment
Unknown
Registered
2014-12-16
Start date
2015-03-18
Completion date
Unknown
Last updated
2015-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivity in patients with untreated ADHD.

Interventions

Trade Name: Medikinet Pharmaceutical Form: Tablet INN or Proposed INN: METHYLPHENIDATE CAS Number: 113-45-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Phar

Sponsors

Landstinget Västmanland
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 18 years old or older. 2. ADHD is diagnosed according to DSM-5 criteria. 3. Qb-score 1.3 or higher on any of the weighted summary parameters QbActivity, QbInAttention or QbImpulsivity on the QbTest. 4. Patiens are given their written informed consent to participate in the study. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Affected by alcohol or drugs during the last month. 2. Untreated severe comorbid psychiatric or somatic illness. 3. Bloodpressure 150/95 or higher. 4. irregular pulse, or pulse 100 or higher. 5. No counter indications according to the Medikinet pill. 6. Concurrent clinical diagnosis that significantly could affect test performance. 7. Concurrent prescription of medicines for ADHD or medicines that significantliy could affect test performance.

Design outcomes

Primary

MeasureTime frame
Main Objective: To examine the effects of expectations, medication and placebo on objective and self-rated performance on ADHD core signs during the Quantified Behavior Test.;Secondary Objective: Not applicable.;Primary end point(s): Primary outcom variables are the weighted summary parameters QbActivity, QbInattention and QbImpulsivity on the Qb Test plus.;Timepoint(s) of evaluation of this end point: December 2016—

Secondary

MeasureTime frame
Secondary end point(s): Secondary outcom variables are self-rated scales concerning expected and experienced performance on the Qb Test, help from the pill, and perceived severity on the task.;Timepoint(s) of evaluation of this end point: December 2016—

Countries

Sweden

Contacts

Public ContactBlanca Domingo

Landstinget Västmanland

blanca.domingo.arnaiz@ltv.se004621175931

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026